Squarepoint Ops LLC Cuts Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Squarepoint Ops LLC reduced its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB) by 4.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,185 shares of the biotechnology company’s stock after selling 482 shares during the quarter. Squarepoint Ops LLC’s holdings in AnaptysBio were worth $280,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. StemPoint Capital LP lifted its stake in shares of AnaptysBio by 499.0% during the 1st quarter. StemPoint Capital LP now owns 269,548 shares of the biotechnology company’s stock worth $6,070,000 after acquiring an additional 224,548 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in AnaptysBio by 38.2% during the second quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company’s stock valued at $7,684,000 after buying an additional 84,795 shares during the period. Platinum Investment Management Ltd. bought a new position in shares of AnaptysBio in the 1st quarter worth $1,490,000. Cubist Systematic Strategies LLC purchased a new stake in shares of AnaptysBio during the second quarter valued at about $1,360,000. Finally, Susquehanna Fundamental Investments LLC acquired a new stake in AnaptysBio in the first quarter valued at approximately $1,221,000.

AnaptysBio Price Performance

Shares of NASDAQ ANAB opened at $33.22 on Friday. AnaptysBio, Inc. has a 1 year low of $13.36 and a 1 year high of $41.31. The company has a market capitalization of $911.22 million, a P/E ratio of -5.23 and a beta of -0.29. The company has a 50 day simple moving average of $35.21 and a 200-day simple moving average of $28.75.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($1.71) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.82). AnaptysBio had a negative return on equity of 255.68% and a negative net margin of 558.25%. The company had revenue of $10.97 million during the quarter, compared to analyst estimates of $25.85 million. As a group, research analysts expect that AnaptysBio, Inc. will post -6.84 EPS for the current year.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the completion of the transaction, the chief financial officer now owns 4,744 shares in the company, valued at $189,333.04. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other AnaptysBio news, CFO Dennis Mulroy sold 12,220 shares of the stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $39.91, for a total value of $487,700.20. Following the sale, the chief financial officer now directly owns 4,744 shares of the company’s stock, valued at approximately $189,333.04. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, Director Hollings Renton sold 10,000 shares of AnaptysBio stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $30.64, for a total value of $306,400.00. Following the sale, the director now directly owns 1,950 shares of the company’s stock, valued at $59,748. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,940 shares of company stock valued at $1,251,836 in the last three months. 33.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

ANAB has been the topic of several research analyst reports. HC Wainwright reissued a “buy” rating and set a $55.00 target price on shares of AnaptysBio in a research report on Wednesday, August 14th. Wedbush restated an “outperform” rating and set a $42.00 target price on shares of AnaptysBio in a research report on Thursday, September 26th. JPMorgan Chase & Co. boosted their price target on shares of AnaptysBio from $69.00 to $75.00 and gave the stock an “overweight” rating in a report on Wednesday, August 7th. Finally, Truist Financial increased their target price on AnaptysBio from $20.00 to $30.00 and gave the company a “hold” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $51.10.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.